Bacterial Meningitis Treatment Guidelines

Introduction to Ceftazidime-Avibactam

The Infectious Diseases Society of America recommends that ceftazidime-avibactam has a limited established role in the treatment of bacterial meningitis and should be reserved for specific cases of multidrug-resistant Gram-negative meningitis, particularly those caused by carbapenem-resistant organisms producing KPC or OXA-48 carbapenemases 1
For empiric treatment of bacterial meningitis, the combination of vancomycin plus either ceftriaxone or cefotaxime remains the standard of care, as recommended by the Infectious Diseases Society of America 1
Traditional third-generation cephalosporins (ceftriaxone, cefotaxime) are first-line agents for most common meningeal pathogens, according to the Infectious Diseases Society of America 1
Ceftazidime-avibactam is a novel antimicrobial combination used to treat serious multidrug-resistant Gram-negative bacterial infections, consisting of the third-generation cephalosporin ceftazidime and the non-β-lactam β-lactamase inhibitor avibactam 2

Ceftazidime-avibactam restores activity against bacteria producing Ambler class A β-lactamases (including ESBLs and KPC carbapenemases), Class C (AmpC) β-lactamases, and some class D enzymes (e.g., OXA-48) 2
Avibactam does not inhibit class B metallo-β-lactamase enzymes (MBLs) such as NDM, VIM, or IMP 2
The combination of ceftazidime-avibactam is effective against Ambler class A (KPC) carbapenemases, Class C (AmpC) β-lactamases, and certain class D (OXA-48) carbapenemases 3

For metallo-β-lactamase-producing organisms (NDM, VIM, IMP), ceftazidime-avibactam alone is ineffective and must be combined with aztreonam, as recommended by the European Society of Clinical Microbiology and Infectious Diseases 4
The Infectious Diseases Society of America recommends using ceftazidime-avibactam for KPC or OXA-48-producing bacteria, and ceftazidime-avibactam plus aztreonam for metallo-β-lactamase producers (NDM, VIM, IMP) 4
For KPC-3 producing organisms, some experts recommend combination therapy with a carbapenem or colistin due to potential resistance development 2
For metallo-β-lactamase-producing infections, ceftazidime-avibactam combined with aztreonam is suggested as a preferential choice, with lower 30-day mortality (19.2% vs 44%, p=0.007) and lower clinical treatment failure rates compared to other active antimicrobial agents 4

The standard adult dose of ceftazidime-avibactam for meningitis is 2.5 grams (2g ceftazidime + 0.5g avibactam) IV every 8 hours, infused over 2 hours 4, 2
Dose adjustment is required for patients with impaired renal function, with the standard dosage being appropriate for patients with creatinine clearance (CrCl) >50 mL/min 2
Adjusting for renal impairment and considering higher doses or more frequent administration for meningitis to ensure adequate CSF levels is recommended 4

Ceftazidime-avibactam has a safety profile consistent with ceftazidime alone, with no differences in frequency of adverse effects including liver and renal function compared to other antimicrobial regimens 2
Ceftazidime-avibactam is strongly recommended for treating infections caused by carbapenem-resistant bacteria that produce serine carbapenemases, as it significantly reduces mortality and treatment failure compared to other antimicrobial options, with a reduction of 182 fewer deaths per 1000 patients (RR 0.55, 95% CI 0.42-0.72) and 307 fewer treatment failures per 1000 patients (RR 0.49, 95% CI 0.34-0.70) 4
Ceftazidime-avibactam treatment may result in 179 fewer pathogen eradication failures per 1000 patients and 95 fewer cases of acute renal injury per 1000 patients compared to other antimicrobial therapies 4
For KPC-producing bacteria, ceftazidime-avibactam has shown superior outcomes compared to colistin-based regimens, with a 64% probability of better outcomes (95% CI 57%-71%) 3

Resistance to ceftazidime-avibactam can develop during treatment, particularly with KPC-3 producing organisms 3
Resistance to ceftazidime-avibactam has been reported, with mechanisms including mutations in the KPC enzyme that disrupt avibactam binding, and resistance rates of 3.7-8.1% have been observed in treated patients 3
Monitoring CSF cultures to confirm sterilization, watching for emergence of resistance during therapy, and monitoring for adverse effects consistent with ceftazidime (seizures, hypersensitivity reactions) is recommended 4
It is essential to confirm susceptibility by determining carbapenemase type and testing ceftazidime-avibactam susceptibility 4